Rhodes J M, Potter B J, Brown D J, Jewell D P
Gastroenterology. 1982 Jun;82(6):1327-34.
Studies were undertaken to determine the incidence and nature of serum chemotaxis inhibitors in patients with Crohn's disease and ulcerative colitis. Sera from patients with active Crohn's disease were shown to contain chemotactic factor-directed inhibitory activity. The molecular size of the inhibitor estimated by gel filtration is similar to the 7S gamma-globulins and it is precipitable by 40% ammonium sulfate. Less marked inhibitory activity is present in the same fractions of sera from patients with ulcerative colitis and from healthy controls, suggesting that it represents increased activity of one or more normal serum globulins. Leukocyte-directed serum inhibitors have also been demonstrated in patients with Crohn's disease and ulcerative colitis, particularly in patients with active disease. In Crohn's disease the presence of serum chemotactic factor inhibitors may explain the diminished chemotaxis of neutrophils into skin window chambers reported previously. The inhibitors are nonspecific and are probably secondary to the disease state but may have some bearing on the nature of the mucosal inflammation.
开展了多项研究以确定克罗恩病和溃疡性结肠炎患者血清趋化性抑制剂的发生率及性质。结果显示,活动期克罗恩病患者的血清含有趋化因子导向抑制活性。通过凝胶过滤法估算,该抑制剂的分子大小与7Sγ球蛋白相似,且可被40%硫酸铵沉淀。溃疡性结肠炎患者及健康对照者血清的相同组分中,抑制活性则不那么明显,这表明它代表一种或多种正常血清球蛋白的活性增加。在克罗恩病和溃疡性结肠炎患者中也证实存在白细胞导向血清抑制剂,尤其是活动期患者。在克罗恩病中,血清趋化因子抑制剂的存在可能解释了先前报道的中性粒细胞向皮肤窗小室趋化性减弱的现象。这些抑制剂是非特异性的,可能继发于疾病状态,但可能与黏膜炎症的性质有关。